Strides gets USFDA approval for two drugs
Strides Shasun announced that its wholly-owned subsidiary Strides Pharma Global Pte. had received the final approval for anti-inflammatory, pain-relieving Ibuprofen tablets, 200 mg, from the USFDA. It also received a tentative approval for its Para IV filing of Milnacipran Hydrochloride tablets from the USFDA. These tablets, meant to treat fibromyalgia that affects tendons, ligaments and supporting tissues.